About Metagenomi
Metagenomi is a company based in Berkeley (United States) founded in 2016 by Brian Thomas.. Metagenomi has raised $376.37 million across 6 funding rounds from investors including Moderna, Bayer and Marshall Wace. The company has 202 employees as of December 31, 2024. Metagenomi operates in a competitive market with competitors including Beam Therapeutics, DNAnexus, eGenesis, Cytel and Korro Bio, among others.
- Headquarter Berkeley, United States
- Employees 202 as on 31 Dec, 2024
- Founders Brian Thomas
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Metagenomi, Inc.
-
Annual Revenue
$52.3 M16.84as on Dec 31, 2024
-
Net Profit
$-78.06 M-14.36as on Dec 31, 2024
-
EBITDA
$-83.49 M-12.4as on Dec 31, 2024
-
Total Equity Funding
$376.37 M (USD)
in 6 rounds
-
Latest Funding Round
$100 M (USD), Series B
Dec 20, 2022
-
Investors
Moderna
& 21 more
-
Employee Count
202
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Metagenomi
Metagenomi is a publicly listed company on the NASDAQ with ticker symbol MGX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Metagenomi
Metagenomi has successfully raised a total of $376.37M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series B — $100.0M
-
First Round
First Round
(02 Aug 2019)
- Investors Count 22
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2022 | Amount | Series B - Metagenomi | Valuation | Novo Holdings , Catalio Capital Management | |
| Jan, 2022 | Amount | Series B - Metagenomi | Valuation | PFM Health Sciences , Farallon Capital Management | |
| Mar, 2021 | Amount | Series A - Metagenomi | Valuation | RA Capital Management , Bayer |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Metagenomi
Metagenomi has secured backing from 22 investors, including venture fund and institutional investors. Prominent investors backing the company include Moderna, Bayer and Marshall Wace. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Venture capital is provided to biomedical technology startups.
|
Founded Year | Domain | Location | |
|
Investments in healthcare companies are made by SymBiosis.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Metagenomi
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Metagenomi
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Metagenomi Comparisons
Competitors of Metagenomi
Metagenomi operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, DNAnexus, eGenesis, Cytel and Korro Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| domain | founded_year | HQ Location |
Cloud-based genome informatics and data management are provided.
|
|
| domain | founded_year | HQ Location |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| domain | founded_year | HQ Location |
Data analysis and statistical solutions are provided for life sciences.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Metagenomi
Frequently Asked Questions about Metagenomi
When was Metagenomi founded?
Metagenomi was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Where is Metagenomi located?
Metagenomi is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Who is the current CEO of Metagenomi?
Brian Thomas is the current CEO of Metagenomi. They have also founded this company.
Is Metagenomi a funded company?
Metagenomi is a funded company, having raised a total of $376.37M across 6 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Aug 02, 2019.
How many employees does Metagenomi have?
As of Dec 31, 2024, the latest employee count at Metagenomi is 202.
What is the annual revenue of Metagenomi?
Annual revenue of Metagenomi is $52.3M as on Dec 31, 2024.
What does Metagenomi do?
Metagenomi was founded in 2016 and is based in Berkeley, United States. Digital gene editing technologies are advanced by the company within the biotechnology sector for drug development purposes. A next-generation tool has been engineered to support drug enhancement and design. Operations center on creating editing solutions for therapeutic applications, with a focus on precision in genetic modifications.
Who are the top competitors of Metagenomi?
Metagenomi's top competitors include DNAnexus, eGenesis and Tessera Therapeutics.
Is Metagenomi publicly traded?
Yes, Metagenomi is publicly traded on NASDAQ under the ticker symbol MGX.
Who are Metagenomi's investors?
Metagenomi has 22 investors. Key investors include Moderna, Bayer, Marshall Wace, Citadel, and RA Capital.
What is Metagenomi's ticker symbol?
The ticker symbol of Metagenomi is MGX on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.